.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,375,111

« Back to Dashboard

Claims for Patent: 7,375,111

Title:Compositions for affecting weight loss
Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance .alpha.-MSH activity.
Inventor(s): Weber; Eckard (San Diego, CA), Cowley; Michael Alexander (Portland, OR)
Assignee: Orexigen Therapeutics, Inc. (San Diego, CA)
Application Number:10/828,795
Patent Claims: 1. A composition for affecting weight loss comprising: (a) a sustained release formulation of bupropion or a pharmaceutically acceptable salt thereof in an amount effective to induce weight loss in an individual; and (b) a sustained release formulation of naltrexone or a pharmaceutically acceptable salt thereof in an amount effective to enhance the weight loss effect of the bupropion or salt thereof; wherein said composition is in a single oral dosage form fixed combination.

2. The composition of claim 1, wherein said composition comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof.

3. The composition of claim 1, wherein said composition comprises about 30 mg to about 500 mg of bupropion or a pharmaceutically acceptable salt thereof.

4. The composition of claim 1, wherein said composition comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof, and about 30 mg to about 500 mg of bupropion or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition for affecting weight loss comprising: (a) a sustained release formulation of bupropion or a pharmaceutically acceptable salt thereof in an amount effective to induce weight loss in an individual; (b) a sustained release formulation of naltrexone or a pharmaceutically acceptable salt thereof in an amount effective to enhance the weight-reducing effect of the bupropion or salt thereof; and a pharmaceutically acceptable excipient, diluent, or carrier, wherein said composition is formulated into a single oral fixed combination dosage form.

6. The pharmaceutical composition of claim 5, wherein said composition comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof.

7. The pharmaceutical composition of claim 5, wherein said composition comprises about 30 mg to about 500 mg of bupropion or a pharmaceutically acceptable salt thereof.

8. The pharmaceutical composition of claim 5, wherein said composition comprises about 5 mg to about 50 mg of naltrexone or a pharmaceutically acceptable salt thereof, and about 30 mg to about 500 mg of bupropion or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc